Literature DB >> 25925232

Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.

Marc K Halushka1, George Eng, A Bernard Collins, Daniel P Judge, Marc J Semigran, James R Stone.   

Abstract

Accurate and rapid classification of cardiac amyloidosis is important for patient management. We have optimized the use of serum free light chain kappa and lambda values to differentiate immunoglobulin light chain amyloid (AL) amyloidosis from transthyretin amyloid and amyloid A using 85 cases of tissue-proven cardiac amyloidosis, in which there was direct classification of amyloidosis by mass spectrometry or immunofluorescence. The serum free light chain kappa/lambda ratios were non-overlapping for the three major groups: AL-lambda (0.01-0.41, n = 30), non-AL (0.52-2.7, n = 43), and AL-kappa (6.7-967, n = 12). A kappa/lambda ratio value between 0.5 and 5.0 had 100 % sensitivity and 100 % specificity for distinguishing AL amyloidosis from non-AL amyloidosis. This optimized range for serum light chain kappa/lambda ratio provides extremely robust classification of cardiac amyloidosis. Cases of cardiac amyloidosis in which the serum kappa/lambda free light chain ratio falls close to these new cutoff values may benefit most from direct amyloid subtyping.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25925232     DOI: 10.1007/s12265-015-9628-2

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  24 in total

1.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Authors:  A R Bradwell; H D Carr-Smith; G P Mead; L X Tang; P J Showell; M T Drayson; R Drew
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

2.  2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology.

Authors:  Ornella Leone; John P Veinot; Annalisa Angelini; Ulrik T Baandrup; Cristina Basso; Gerald Berry; Patrick Bruneval; Margaret Burke; Jagdish Butany; Fiorella Calabrese; Giulia d'Amati; William D Edwards; John T Fallon; Michael C Fishbein; Patrick J Gallagher; Marc K Halushka; Bruce McManus; Angela Pucci; E René Rodriguez; Jeffrey E Saffitz; Mary N Sheppard; Charles Steenbergen; James R Stone; Carmela Tan; Gaetano Thiene; Allard C van der Wal; Gayle L Winters
Journal:  Cardiovasc Pathol       Date:  2011-12-03       Impact factor: 2.185

3.  Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology.

Authors:  James R Stone; Cristina Basso; Ulrik T Baandrup; Patrick Bruneval; Jagdish Butany; Patrick J Gallagher; Marc K Halushka; Dylan V Miller; Robert F Padera; Stanley J Radio; Mary N Sheppard; Kim Suvarna; Carmela D Tan; Gaetano Thiene; Allard C van der Wal; John P Veinot
Journal:  Cardiovasc Pathol       Date:  2011-02-24       Impact factor: 2.185

4.  Serum test for assessment of patients with Bence Jones myeloma.

Authors:  Arthur R Bradwell; Hugh D Carr-Smith; Graham P Mead; Timothy C Harvey; Mark T Drayson
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

Review 5.  Amyloidosis and the heart: a comprehensive review.

Authors:  Keyur B Shah; Yoshio Inoue; Mandeep R Mehra
Journal:  Arch Intern Med       Date:  2006-09-25

6.  Quantitative serum free light chain assay--analytical issues.

Authors:  Jill Tate; Sheree Bazeley; Stephen Sykes; Peter Mollee
Journal:  Clin Biochem Rev       Date:  2009-08

7.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

Review 8.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

Review 9.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

10.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

View more
  2 in total

Review 1.  Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.

Authors:  Wengen Chen; Van-Khue Ton; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2018-03-08       Impact factor: 2.931

2.  Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease.

Authors:  Stephen J Horgan; Chris J Watson; Nadia Glezeva; Pat Collier; Roisin Neary; Isaac J Tea; Niamh Corrigan; Mark Ledwidge; Ken McDonald; John A Baugh
Journal:  J Cardiovasc Transl Res       Date:  2015-11-17       Impact factor: 4.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.